Co-Authors
This is a "connection" page, showing publications co-authored by David Lye and Yi-Hao Chan.
Connection Strength
1.342
-
Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. Front Immunol. 2021; 12:680188.
Score: 0.238
-
Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2. EMBO Mol Med. 2021 06 07; 13(6):e14045.
Score: 0.237
-
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. Open Forum Infect Dis. 2021 Jun; 8(6):ofab156.
Score: 0.234
-
Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clin Infect Dis. 2021 11 02; 73(9):e2932-e2942.
Score: 0.061
-
The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2021 05 23; 7(3):e48-e51.
Score: 0.059
-
Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. EBioMedicine. 2021 Apr; 66:103319.
Score: 0.059
-
Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife. 2021 03 23; 10.
Score: 0.058
-
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021 Jun; 2(6):e240-e249.
Score: 0.058
-
Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nat Commun. 2020 10 16; 11(1):5243.
Score: 0.057
-
Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19. Open Forum Infect Dis. 2020 Sep; 7(9):ofaa375.
Score: 0.056
-
Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020 08 29; 396(10251):603-611.
Score: 0.056
-
Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. Clin Transl Immunology. 2020; 9(7):e1160.
Score: 0.056
-
Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. Clin Transl Immunology. 2020; 9(7):e1159.
Score: 0.056
-
Linear B-cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease severity. EBioMedicine. 2020 Aug; 58:102911.
Score: 0.056